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Objeti vo: Determinar a existência de associação entre os níveis 
de mieloperoxidase no fl uido crevicular gengival (MFCG), 
periodonti te e câncer de pâncreas.
Método: Neste estudo duplo cego randomizado, 66 indivíduos 
de classe média foram divididos nos quatro grupos a seguir e 
ti veram os níveis de MFCG analisados: câncer de pâncreas com 
periodonti te, câncer de pâncreas sem periodonti te, periodonti te 
sem câncer de pâncreas, e normal (33:33 mulheres:homens; 
faixa etária: 30-65 aos). A periodonti te foi defi nida pela presença 
de pelo menos 7 dentes com profundidade de sondagem 
(PS) maior que 5 mm e perda óssea radiográfi ca perceptí vel 
maior que 30% nos síti os dentários, determinada por meio 
de uma série de radiografi as intra-orais de boca completa. 
Medidas clínicas da severidade da doença periodontal, tais 
como sangramento à sondagem (SS), PS e perda do nível de 
inserção clínica (NIC), foram determinadas usando uma sonda 
periodontal convencional.
Resultados: Os níveis médios de MFCG foram signifi cantemente 
maiores nos pacientes com câncer de pâncreas e periodonti te, 
em comparação aos outros pacientes. Os níveis médios de MFCG 
em pacientes sem câncer de pâncreas e pacientes com câncer 
de pâncreas e sem periodonti te foram 0,68 ± 0,32 U/mL and 
0,84±0,32 U/mL, respecti vamente. Houve correlação positi ve 
entre os níveis de MFCG e as percentagens de SS, NIC e PS. 
Pacientes com câncer de pâncreas e periodonti te apresentaram 
maiores percentagens de SS, PS e NIC em comparação aos 
pacientes sem câncer de pâncreas (p<0,05).
Conclusão: A análise dos níveis de MFCG pode ser úti l na 
detecção do risco de câncer de pâncreas em pacientes com 
periodonti te.
Objecti ve: To determine the associati on between levels of GCF 
myeloper oxidase (GM), periodonti ti s and pancreati c cancer.
Method: This was a double blind randomized study. Sixty 
six subjects middle class divided into four group such as 
pancreati c cancer with periodonti ti s, pancreati c cancer without 
periodonti ti s, non pancreati c cancer with periodonti ti s and 
normal (33:33 M:F; range 30-65 years) were selected for the 
study were recruited for the study and GM levels were analyzed. 
Periodonti ti s in pati ents was defi ned of the presence of at least 
seven teeth with probing depth > 5mm and demonstrable 
radiographic bone loss >30 percent of tooth sites by a full 
mouth intraoal radiographic series. Clinical measures of the 
severity of periodontal disease, such as bleeding on probing, 
probing depth (PD) and loss of clinical att achment level (CL) 
were determined using a conventi onal periodontal probe.
Results: GM levels were signifi cantly higher in pancreati c 
cancer with periodonti ti s as compared to others. The mean 
GM level in non pancreati c cancer and pancreati c cancer 
without periodonti ti s were 0.68±0.32U/ml and 0.84±0.32 U/
ml, respecti vely. A positi ve correlati on was noted between GCF 
meyloperoxidase and percentage of BP, CL and PD. Pancreati c 
cancer with periodonti ts, pancreati c exhibited greater BP, PD 
and CL as compared to non- pancreati c cancer (p<0.05).
Conclusion: Thus, measurement of GM may prove to be useful 
in detecti on risk of pancreati c cancer in periodonti ti s pati ents.
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INTRODUCTION
MATERIAL AND METHODS
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Periodontal disease, a common chronic oral 
infl ammatory disease, is characterized by destructi on of 
soft  ti ssue and bone. The crucial casual relati on might 
be established by prospecti ve treatment studies, which 
elucidate the connecti on between treatment of poor 
dental health and systemic infl ammatory markers1,2.
The oral cavity provides a gateway between the 
external environment and the gastrointesti nal tract, and it 
facilitates both food ingesti on and digesti on. Oral hygiene 
and tooth loss can potenti ally aﬀ ect gastrointesti nal fl ora 
and nutriti onal status, and thus they have implicati ons 
for the development of chronic diseases.
Poor dental health, tooth loss, or both have been 
associated with increased risk for gastrointesti nal 
malignancies, including oral , esophageal , and gastric 
cancers3-7. It has been reported a positi ve associati on 
between self-reported periodontal disease and risk of 
pancreati c cancer in a cohort of 51 529 predominantly 
white US men aged 40- 75 years in the Health Professionals 
Follow- Up Study (HPFS)8.
It has been reported that  myeloperoxidase levels 
increase in pancreati c cancer9. Biomarkers of periodontal 
acti vity may be obtained from potenti al proteolyti c and 
hydrolyti c enzymes of infl ammatory cell origin10.
It has been also observed that increased 
myeloperoxidase which is present in azurophilic granules 
of polymorphonuclear neutrophils, acti vity in periodonti ti s 
as compared to controls11. Myeloperoxidase considered a 
promising marker of periodontal infl ammati on12,13.
Hence, the present study was planned to determine 
the relati onship between GCF myeloperoxidase (GM) 
levels in periodonti ti s and pancreati c cancer.
This was a double blind randomized study. Sixty 
six subjects middle class (14:12 M:F; range 30-65 years) 
were selected for the study. Pati ents were excluded from 
the study if they had alcholic or chronic smoker. Thrity 
fi ve diagnosti c pati ents middle class non smoker and non 
alcoholic (20:15; range 33-62 years ) of pancreati c cancer 
were selected and oral examinati on were done without 
any other systemic diseases.
The middle class periodontal cases comprised 
20 subjects (10:10 F:M; range 24-60 years). The 
control middle class (healthy), non periodontal cases 
comprised 11 subjects (6:5 F:M; range 28-63 years), 
none of whom exhibited clinical signs over 5 mm or any 
clinical att achment loss. In none of the parti cipants was 
cardiovascular disease or any other ongoing general 
disease or infecti ons diagnosed. 
Periodonti ti s in pati ents was defi ned of the presence 
of at least seven teeth with probing depth > 5mm and 
demonstrable radiographic bone loss >30 percent of 
tooth sites by a full mouth intraoal radiographic series. 
All parti cipants had chronic periodonti ti s who had not 
received any surgical therapy previously. All subjects 
were systemically healthy, with no medical conditi ons 
that would aﬀ ect their parti cipati on in the study.
The exclusion criteria was a course of anti -
infl ammatory or anti microdial therapy within the 
previous 3 months, a history of regular use of mouth 
washes, use of any vitamin supplementati on or mucosal 
lesions, chemotherapy, rediati on therapy, or medicati ons 
that cause xerostmia. Informed consent was obtained 
from the subjects.
Clinical measures of the severity of periodontal 
disease, such as bleeding on probing, probing depth 
(PD) and loss of clinical att achment level (CL) were 
determined using a conventi onal periodontal probe 
(Hu-Friedy Chicago, IL). At six sites around each tooth 
(Mesio-buccal, midbuccal, disto-buccal, mesio-lingual, 
mid-lingual and disto-lingual, excluding third molars. The 
probe was directed parallel to the long axis of the tooth. 
Clinical loss of att achment measurement were made 
from the cemento-enamel juncti on to bott om of the 
sulcus. GCF sampling and processing were done as has 
been described in detail elsewhere12. MPO acti vity (GM) 
is analysed as previous studies13.
Relati onships between GM; probing depths and 
bleeding on probing, were analysed using a performed 
during SPSS (version 11.0, Chicago, USA).
RESULTS AND DISCUSSION
he mean GM level in non pancreati c cancer and 
pancreati c cancer without periodonti ti s were 0.68±0.32U/
ml and 0.84±0.32 U/ml respecti vely (Table 1, p<0.05). To 
our knowledge, this is the fi rst study to evaluate GCF 
meyloperoxidase level in periodonti ti s in pancreati c and 
non pancreati c cancer.
In the present study, high level as GCF 
meyloperoxidase were observed in pancreati c cancer 
pati ents and level were sti ll higher in pancreati c cancer as 
compared to non- pancreati c cancer (Table 1, p<0.05).
A positi ve correlati on was noted between GCF 
meyloperoxidase and percentage of BP, CL and PD 
(Table 1). In the present study, pancreati c cancer with 
periodonti ts, pancreati c exhibited greater BP, PD and CL 
as compared to non- pancreati c cancer (Table 1, p<0.05).
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CONCLUSION
Although MPO is involved in the pathogenesis 
of infl ammatory periodontal diseases and pancreati c 
cancer, it is also found in clinically healthy sites in lower 
levels than the periodentally diseases sites9,13,14.
To the best of our knowledge, there is no published 
study determining the eﬀ ects of pancreati c on GM 
levels. Therefore, we could not compare the results of 
present study with other results. Several mechanisms 
could potenti ally explain the observati ons from this 
study. Infl ammati on appears to play an important 
role in pancreati c cancer pathogenesis8, although the 
infl ammatory mediators that lead to the development of 
pancreati c cancer remain poorly defi ned.
An associati on between periodontal disease 
and systemic infl ammati on has been observed using 
biomarkers15. We hypothesize  that  periodontal 
disease may promote pancreati c carcinogenesis 
through infl ammati on through oxidati ve enzyme such 
as myeloperoxidase. While some authors belived 
that periodontal disease could infl uence pancreati c 
carcinogenesis through increased generati on of 
carcinogens, namely nitrosamines16.
Nitrosamines and gastric acidity have been 
hypothesized to have an important role in pancreati c 
cancer; numerous studies support this hypothesis17. We 
were not included more oxidati ve stress marker and 
more samples size as well as the same marker in saliva 
and serum to clarifi ed the correlati on between two 
diseases. GCF myeloperoxidase can be easily measured 
and may prove to be useful in identi fying pati ents at risk 
of pancreati c cancer.
Further study is required on large scale while 
considering the risk factors and eﬀ ect of periodonti ti s 
treatment on myeloperoxidase level in saliva and serum.
Table 1. Level of GCF myeloperoxidase (in U/ml), probing depth and bleeding on probing in pancreati c cancer 
with periodonti ti s (A), pancreati c cancer without periodonti ts (B), no pancreati c cancer with periodonti ti s (C), 
Normal healthy ie no pancreati c cancer and periodonti ti s (D) mean±S.D.
Parameters A B C D
GCF myeloperoxidase (in U/ml) 1.18 ±0.29 1.02±0.24  0.84±0.32 0.68±0.32
Probing depth (in mm) 5.63±0.13 1.62±0.23 3.56±0.33 72±0.12
Bleeding on probing(in%) 6.53±0.6 27.6±0.30 5.01±0.1  9.4± 0.30
Clinical loss of att achment 4.82±0.28 .23±0.14 2.8±0.22 .72±0.13
GM may prove to be useful in detecti on risk of 
pancreati c cancer in periodonti ti s pati ents this study 
also supports the infl ammatory mechanism of pancreati c 
cancer.
REFERENCES
1. Zhu J, Quyyumi AA, Norman JE, Csako G, Waclawiw MA, 
Shearer GM, Epstein SE. Eﬀ ects of total pathogen burden on 
coronary artery disease risk and C-reacti ve protein levels. Am J 
Cardiol 2000; 85(2):140-46.
2. Noack B, Genco RJ, Trevisan M, Grossi S, Zambon JJ, De 
Nardin E. Periodontal infecti ons contribute to elevated systemic 
C-reacti ve protein level. J Periodontol 2001; 72(9):1221-7.
3. Zheng TZ, Boyle P, Hu HF, Duan J, Jian PJ, Ma DQ, Shui LP, Niu 
SR, Scully C, MacMahon B. Denti ti on, oral hygiene, and risk of 
oral cancer: a case-control study in Beijing, People’s Republic of 
China. Cancer Causes Control 1990; 1(3):235-41.
4. Garrote LF, Herrero R, Reyes RM, Vaccarella S, Anta JL, 
Ferbeye L, Muñoz N, Franceschi S. Risk factors for cancer of the 
oral cavity and oro-pharynx in Cuba. Br J Cancer 2001; 85(1): 
46-54.
5. Velly AM, Franco EL, Schlecht N, Pintos J, Kowalski LP, Oliveira 
BV, Curado MP. Relati onship between dental factors and risk of 
upper aerodigesti ve tract cancer. Oral Oncol 1998; 34(4):284-
91.
6. Abnet CC, Qiao YL, Mark SD, Dong ZW, Taylor PR, Dawsey 
SM. Prospecti ve study of tooth loss and incident esophageal 
and gastric cancers in China. Cancer Causes Control 2001; 
12(9):847-54.
7. Watabe K, Nishi M, Miyake H, Hirata K. Lifestyle and gastric 
cancer: a case-control study. Oncol Rep 1998; 5(5):1191-4.
8. Michaud DS, Joshipura K, Giovannucci E, Fuchs CS. A 
prospecti ve study of periodontal disease and pancreati c cancer 
in US male health professionals. J Natl Cancer Inst 2007; 99(2): 
171-5 .
9.  Wheatley-Price P, Asomaning K, Reid A, Zhai R, Su L, Zhou 
W, Zhu A, Ryan DP, Christi ani DC, Liu G. Myeloperoxidase and 
superoxide dismutase polymorphisms are associated with 
an increased risk of developing pancreati c adenocarcinoma. 
Cancer 2008; 112(5):1037-42.
10. Eley BM, Cox SW. Advances in periodontal diagnosis 
proteolyti c and hydrolyti c enzymes link with periodonti ti s. Br 
Dent 1984; 184(7):323-8.
11. Cao CF, Smith QT. Crevicular fl uid myeloperoxidase at 
healthy, gingiviti s and periodonti ti s sites. J Clin Periodontal 
1989; 16(1):17-20.
12. Yamalik N, Cağlayan F, Kilinç K, Kilinç A, Tümer C. The 
importance of data presentati on regarding gingival crevicular 
fl uid myeloperoxidase and elastase like acti vity in periodontal 
disease and health status. J Periodontol 2000; 71(3):460-7.
13. Kaner D, Bernimoulin JP, Kleber BM, Heizmann WR, 
Friedmann A. Gingival crevicular fl uid levels of calprotecti n 
and myeloperoxidase during therapy for generalized aggressive 
periodonti ti s. J Periodontal Res 2006; 41(2):132-9.
14. Tervaharti ala T, Kontti  nen YT, INgman T, Häyrinen-Immonen 
R, Ding Y, Sorsa T. Cathepsin G in gingival ti ssue and crevicular 
fl uid in adult periodonti ti s. J Clin Periodontol 1996; 23(2):68-
75.
Pesq Bras Odontoped Clin Integr, João Pessoa, 10(1):79-82, jan./abr. 2010
Rai - Gingival Crevicular Fluid Myeloperoxidase in Periodonti ti s and Pancreati c Cancer
82
15. Suzuki K, Ota H, Sasagawa S, Sakatani T, Fujikura T. Assay 
method for myeloperoxidase in human polymorphonuclear 
leukocytes. Anal Biochem 1983; 132(2):345-52.
16. Rai B, Kharb S, Anand SC. Eﬀ ect of treatment of periodonti ti s 
on C-reacti ve protein, ti ssue plasminogen acti vator and high-
serum/low density lipoprotein in cholesterol: a pilot study. J 
Clin Diagn Res 2008; 2(2):786-88.
17. Abnet CC, Kamangar F, Dawsey SM, Stolzenberg-Solomon 
RZ, Albanes D, Pieti nen P, Virtamo J, Taylor PR. Tooth loss 
is associated with increased risk of gastric non-cardia 
adenocarcinoma in a cohort of Finnish smokers. Scand J 
Gastroenterol 2005; 40(6):681-7.
18. Nair J, Ohshima H, Nair UJ, Bartsch H. Endogenous formati on 
of nitrosamines and oxidati ve DNA-damaging agents in tobacco 
users. Crit Rev Toxicol 1996; 26(2):149-61.
Correspondence:
Balwant Rai
Vill. Bhangu, Distt  . Sirsa, P.O. Sahuwala I, India
Mobile Phone: 091-9812185855
E-mail: drbalwantraissct@rediﬀ mail.com
Recebido/Received: 22/04/09
 Revisado/Reviewed: 12/08/09
Aprovado/Approved: 03/09/09
Pesq Bras Odontoped Clin Integr, João Pessoa, 10(1):79-82, jan./abr. 2010
Rai - Gingival Crevicular Fluid Myeloperoxidase in Periodonti ti s and Pancreati c Cancer
